๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Long-term tolerability of fenretinide (4-HPR) in breast cancer patients

โœ Scribed by N. Rotmensz; G. De Palo; F. Formelli; A. Costa; E. Marubini; T. Campa; A. Crippa; G.M. Danesini; M. Delle Grottaglie; M.G. Di Mauro; A. Filiberti; M. Gallazzi; A. Guzzon; A. Magni; W. Malone; L. Mariani; M. Palvarini; M. Perloff; M. Pizzichetta; U. Veronesi

Book ID
119157028
Publisher
Elsevier Science
Year
1991
Weight
711 KB
Volume
27
Category
Article
ISSN
0277-5379

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Randomized trial of fenretinide (4-HPR)
Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: Long-term results
โœ Fausto Chiesa; Nicoletta Tradati; Roberto Grigolato; Patrizia Boracchi; Elia Big ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 84 KB

## Abstract We assessed the efficacy of fenretinide at preventing relapses, new lesions and carcinomas after surgical excision of oral leukoplakia. In a controlled multicenter study, 170 patients operated on for oral leukoplakias with benign postoperative histology were randomized to 200 mg fenreti